Concepedia

David Messersmith

DM

Statistics

Publications

6

Citations

254

H-Index

6

Active since

2003

Affiliations

Vertex Pharmaceuticals (United States)(Current)

David Messersmith is an author at Vertex Pharmaceuticals (United States) specializing in pharmacology, drug discovery, and medicine.

Top concepts

Publications per year

2003–2020

6

Publications

6

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

, , +16

Versatile and Facile Synthesis of Diverse Semisynthetic Tetracycline Derivatives via Pd-Catalyzed Reactions

Mark L. Nelson, Mohamed Y. Ismail, Laura McIntyre et al. · The Journal of Organic Chemistry · 2003 · 50 citations

Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)

Jon H. Come, Philip N. Collier, James A. Henderson et al. · Journal of Medicinal Chemistry · 2018 · 46 citations · Full text

, , +20

Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ

Philip N. Collier, David Messersmith, Arnaud LeTiran et al. · Journal of Medicinal Chemistry · 2015 · 31 citations · Full text

, , +15

2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2

Mark W. Ledeboer, Albert C. Pierce, John P. Duffy et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 27 citations · Full text

, , +8

1–5 of 6